Compare RZLT & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | CGC |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.1M | 299.0M |
| IPO Year | 2011 | 2023 |
| Metric | RZLT | CGC |
|---|---|---|
| Price | $4.00 | $0.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $10.40 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.47 | ★ 84.17 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | $2,517.77 | $6.82 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $0.53 |
| 52 Week High | $11.17 | $2.38 |
| Indicator | RZLT | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 26.28 |
| Support Level | $3.58 | N/A |
| Resistance Level | $4.22 | $0.76 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 35.74 | 0.39 |
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.